A detailed history of Artemis Investment Management LLP transactions in Dexcom Inc stock. As of the latest transaction made, Artemis Investment Management LLP holds 3,784 shares of DXCM stock, worth $430,202. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,784
Previous 7,117 46.83%
Holding current value
$430,202
Previous $883,000 40.66%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 16, 2024

SELL
$114.22 - $140.1 $380,695 - $466,953
-3,333 Reduced 46.83%
3,784 $524,000
Q4 2023

Jan 17, 2024

SELL
$75.49 - $124.16 $20.1 Million - $33 Million
-266,036 Reduced 97.39%
7,117 $883,000
Q3 2023

Oct 16, 2023

SELL
$86.06 - $137.93 $13.4 Million - $21.5 Million
-155,926 Reduced 36.34%
273,153 $25.5 Million
Q2 2023

Jul 19, 2023

BUY
$112.47 - $130.98 $46.8 Million - $54.5 Million
416,258 Added 3246.69%
429,079 $55.1 Million
Q1 2023

May 05, 2023

SELL
$104.0 - $122.92 $8,216 - $9,710
-79 Reduced 0.61%
12,821 $1.49 Million
Q4 2022

Jan 25, 2023

BUY
$84.98 - $122.67 $158,742 - $229,147
1,868 Added 16.93%
12,900 $0
Q3 2022

Oct 25, 2022

BUY
$76.35 - $94.18 $842,293 - $1.04 Million
11,032 New
11,032 $889,000
Q3 2019

Oct 10, 2019

SELL
$35.53 - $43.8 $1.25 Million - $1.54 Million
-35,049 Closed
0 $0
Q2 2019

Jul 24, 2019

SELL
$27.84 - $38.92 $1.02 Million - $1.42 Million
-36,474 Reduced 51.0%
35,049 $5.11 Million
Q1 2019

May 15, 2019

SELL
$28.07 - $38.18 $138,357 - $188,189
-4,929 Reduced 6.45%
71,523 $8.53 Million
Q4 2018

Feb 12, 2019

BUY
$26.99 - $37.37 $240,534 - $333,041
8,912 Added 13.2%
76,452 $9.16 Million
Q3 2018

Nov 09, 2018

BUY
$23.35 - $36.72 $1.58 Million - $2.48 Million
67,540 New
67,540 $9.66 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $43.9B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Artemis Investment Management LLP Portfolio

Follow Artemis Investment Management LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artemis Investment Management LLP, based on Form 13F filings with the SEC.

News

Stay updated on Artemis Investment Management LLP with notifications on news.